Characterization of Cannabis users and products and the experience of negative mental emotions following Cannabis use.
Adverse events
Cannabis
Medical cannabis
Negative mental emotion
Psychiatric adverse events
Journal
European archives of psychiatry and clinical neuroscience
ISSN: 1433-8491
Titre abrégé: Eur Arch Psychiatry Clin Neurosci
Pays: Germany
ID NLM: 9103030
Informations de publication
Date de publication:
11 Jun 2024
11 Jun 2024
Historique:
received:
17
07
2023
accepted:
19
04
2024
medline:
11
6
2024
pubmed:
11
6
2024
entrez:
11
6
2024
Statut:
aheadofprint
Résumé
There is a potential link between cannabis and mental disorders. Cannabis exposure involves in many cases negative mental emotions, which are unpleasant sensations or thoughts. Whereas mild cases of negative mental emotions inflict patient's quality of life, more severe cases lead to therapy discontinuations, or even hospitalizations and death. This study characterizes cannabis users who experienced negative mental emotions after cannabis exposure. The Releaf App database was utilized to evaluate the association between personal and cannabis use characteristics on reporting a negative mental emotion during cannabis exposure. This global mobile lets individuals track real-time cannabis experience use with cannabinoid-based products, containing data points such as gender, age, reasons for use, product type, cannabis composition, and feelings and emotions experienced after cannabis use. Multivariable logistic regression models were constructed, adjusting for potential confounders such as gender and previous experience with cannabis use. The study population comprised 4,435 users, and 34,279 sessions were collected from various countries, mainly from North America, and included in the primary analysis. Reporting on negative mental emotions was associated with users in the age group of 18-30 years. Using cannabis for a mental purpose was associated with a small increase in reporting on negative mental emotions (OR = 1.10, 95%CI [1.03-1.19]). Oral products were associated with reporting on negative mental emotions. THC-dominant products were associated with reporting negative mental emotions compared to balanced products (OR = 1.21, 95%CI [1.06-1.38]). This study suggests that some characteristics of cannabis use, such as young age and oral consumption are associated with negative mental emotions. Further studies should examine the interface between cannabis consumption, characteristics of consumers, and negative emotional experience or even long-term mental disorders.
Identifiants
pubmed: 38861239
doi: 10.1007/s00406-024-01812-0
pii: 10.1007/s00406-024-01812-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
UNODC (2016) Annual prevalence of the use of drugs by region and globally, Statistics and Data. In: UNODC. https://dataunodc.un.org/drugs/prevalence_regional . Accessed 2 Jun 2019
UNODC (2021) Prevalence-general | dataUNODC. In: United Nations. https://dataunodc.un.org/data/drugs/Prevalence-general . Accessed 8 Apr 2021
Cohen K, Weizman A, Weinstein A (2019) Positive and negative effects of cannabis and cannabinoids on health. Clin Pharmacol Ther 105:1139–1147. https://doi.org/10.1002/CPT.1381
doi: 10.1002/CPT.1381
pubmed: 30703255
Karila L, Roux P, Rolland B et al (2014) Acute and long-term effects of cannabis use: a review. Curr Pharm Des 20:4112–4118. https://doi.org/10.2174/13816128113199990620
doi: 10.2174/13816128113199990620
pubmed: 24001294
Sholler DJ, Strickland JC, Spindle TR et al (2021) Sex differences in the acute effects of oral and vaporized cannabis among healthy adults. Addict Biolo. https://doi.org/10.1111/ADB.12968
doi: 10.1111/ADB.12968
National Academies of Sciences E and M, Division H and M, Practice B on PH and PH, Agenda C on the HE of MAER and R (2017) The Health Effects of Cannabis and Cannabinoids. National Academies Press (US)
Rl P, La A, Ra K et al (2020) Medical marijuana, recreational Cannabis, and cardiovascular health: a scientific statement from the american heart association. Circulation 142:E131–E152. https://doi.org/10.1161/CIR.0000000000000883
doi: 10.1161/CIR.0000000000000883
Zenone MA, Snyder J, Crooks V (2021) Selling cannabidiol products in Canada: A framing analysis of advertising claims by online retailers. BMC Public Health 21:1–10. https://doi.org/10.1186/S12889-021-11282-X
doi: 10.1186/S12889-021-11282-X
Marconi A, Di Forti M, Lewis CM et al (2016) Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull 42:1262. https://doi.org/10.1093/SCHBUL/SBW003
doi: 10.1093/SCHBUL/SBW003
pubmed: 26884547
pmcid: 4988731
Di Forti M, Marconi A, Carra E et al (2015) Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2:233–238. https://doi.org/10.1016/S2215-0366(14)00117-5
doi: 10.1016/S2215-0366(14)00117-5
pubmed: 26359901
Moore TH, Zammit S, Lingford-Hughes A et al (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370:319–328. https://doi.org/10.1016/S0140-6736(07)61162-3
doi: 10.1016/S0140-6736(07)61162-3
pubmed: 17662880
Di Forti M, Quattrone D, Freeman TP et al (2019) The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry 6:427–436. https://doi.org/10.1016/S2215-0366(19)30048-3
doi: 10.1016/S2215-0366(19)30048-3
pubmed: 30902669
pmcid: 7646282
Sharpe L, Sinclair J, Kramer A et al (2020) Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. J Transl Med 18:1–21. https://doi.org/10.1186/S12967-020-02518-2/TABLES/5
doi: 10.1186/S12967-020-02518-2/TABLES/5
van Gastel WA, Vreeker A, Schubart CD et al (2014) Change in cannabis use in the general population: a longitudinal study on the impact on psychotic experiences. Schizophr Res 157:266–270. https://doi.org/10.1016/j.schres.2014.04.023
doi: 10.1016/j.schres.2014.04.023
pubmed: 24930951
Ragazzi TCC, Shuhama R, Menezes PR, Del-Ben CM (2018) Cannabis use as a risk factor for psychotic-like experiences: A systematic review of non-clinical populations evaluated with the Community Assessment of Psychic Experiences. Early Interv Psychiatry 12:1013–1023. https://doi.org/10.1111/eip.12693
doi: 10.1111/eip.12693
pubmed: 29927066
Alemany S, Arias B, Fatjó-Vilas M et al (2014) Psychosis-inducing effects of cannabis are related to both childhood abuse and COMT genotypes. Acta Psychiatr Scand 129:54–62. https://doi.org/10.1111/acps.12108
doi: 10.1111/acps.12108
pubmed: 23445265
Brañas A, Barrigón ML, Garrido-Torres N et al (2016) U-shaped curve of psychosis according to cannabis use: New evidence from a snowball sample. J Psychopharmacol 30:1331–1338. https://doi.org/10.1177/0269881116660712
doi: 10.1177/0269881116660712
pubmed: 27539930
Ferdinand RF, Sondeijker F, Van Der Ende J et al (2005) Cannabis use predicts future psychotic symptoms, and vice versa. Addiction (Abingdon, England) 100:612–618. https://doi.org/10.1111/J.1360-0443.2005.01070.X
doi: 10.1111/J.1360-0443.2005.01070.X
pubmed: 15847618
Leweke FM, Piomelli D, Pahlisch F et al (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2:e94. https://doi.org/10.1038/tp.2012.15
doi: 10.1038/tp.2012.15
pubmed: 22832859
pmcid: 3316151
Sorkhou M, Bedder RH, George TP (2021) The behavioral sequelae of cannabis use in healthy people: a systematic review. Front Psychiatry 12:630247. https://doi.org/10.3389/FPSYT.2021.630247/FULL
doi: 10.3389/FPSYT.2021.630247/FULL
pubmed: 33664685
pmcid: 7920961
Chen B, Choi H, Hirsch LJ et al (2017) Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav 76:24–31. https://doi.org/10.1016/J.YEBEH.2017.08.039
doi: 10.1016/J.YEBEH.2017.08.039
pubmed: 28931473
Sockalingam S, Tseng A, Giguere P, Wong D (2013) Psychiatric treatment considerations with direct acting antivirals in hepatitis C. BMC Gastroenterol 13:1–10. https://doi.org/10.1186/1471-230X-13-86/TABLES/4
doi: 10.1186/1471-230X-13-86/TABLES/4
Edinoff AN, Akuly HA, Hanna TA et al (2021) Selective serotonin reuptake inhibitors and adverse effects: a narrative review. Neurol Int 13:387. https://doi.org/10.3390/NEUROLINT13030038
doi: 10.3390/NEUROLINT13030038
pubmed: 34449705
pmcid: 8395812
Mullins CD, Shaya FT, Meng F et al (2005) Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram. Pharmacotherapy 25:660–667. https://doi.org/10.1592/PHCO.25.5.660.63590
doi: 10.1592/PHCO.25.5.660.63590
pubmed: 15899727
Li K, Zhou G, Xiao Y et al (2022) Risk of suicidal behaviors and antidepressant exposure among children and adolescents: a meta-analysis of observational studies. Front Psychiatry 13:880496. https://doi.org/10.3389/FPSYT.2022.880496/BIBTEX
doi: 10.3389/FPSYT.2022.880496/BIBTEX
pubmed: 35693956
pmcid: 9178080
McKinney W & Others (2010) Data structures for statistical computing in python. 51–56
Kluyver T, Ragan-Kelley B, Pérez F, et al (2016) Jupyter Notebooks – a publishing format for reproducible computational workflows. Positioning and Power in Academic Publishing: Players, Agents and Agendas - Proceedings of the 20th International Conference on Electronic Publishing, ELPUB 2016 87–90. https://doi.org/10.3233/978-1-61499-649-1-87
Brooks ME, Kristensen K, van Benthem KJ, et al (2017) glmmtmb balances speed and flexibility among packages for zero-inflated generalized linear mixed modeling. R Journal 9:378–400. https://doi.org/10.32614/RJ-2017-066
Bandoli G, Palmsten K, Chambers CD et al (2018) Revisiting the table 2 fallacy: a motivating example examining preeclampsia and preterm birth. Paediatr Perinat Epidemiol 32:390. https://doi.org/10.1111/PPE.12474
doi: 10.1111/PPE.12474
pubmed: 29782045
pmcid: 6103824
Westreich D, Greenland S (2013) The table 2 fallacy: presenting and interpreting confounder and modifier coefficients. Am J Epidemiol 177:292. https://doi.org/10.1093/AJE/KWS412
doi: 10.1093/AJE/KWS412
pubmed: 23371353
pmcid: 3626058
Bates D, Mächler M, Bolker BM, Walker SC (2015) Fitting linear mixed-effects models using lme4. J Stat Softw 67:1–48. https://doi.org/10.18637/JSS.V067.I01
Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc: Ser B (Methodol) 57:289–300. https://doi.org/10.1111/J.2517-6161.1995.TB02031.X
doi: 10.1111/J.2517-6161.1995.TB02031.X
Diedenhofen B, Musch J (2015) cocor: a comprehensive solution for the statistical comparison of correlations. PLoS ONE 10:e0121945. https://doi.org/10.1371/JOURNAL.PONE.0121945
doi: 10.1371/JOURNAL.PONE.0121945
pubmed: 25835001
pmcid: 4383486
Sami MB, Bhattacharyya S (2018) Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders. J Psychopharmacol 32:825–849
doi: 10.1177/0269881118760662
pubmed: 29591635
pmcid: 6058406
Rubens M (2014) Political and medical views on medical marijuana and its future. Soc Work Public Health 29:121–131. https://doi.org/10.1080/19371918.2013.821351
doi: 10.1080/19371918.2013.821351
pubmed: 24405197
EMCDDA (2023) New psychoactive substances – the current situation in Europe (European Drug Report 2023). https://www.emcdda.europa.eu/publications/european-drug-report/2023/new-psychoactive-substances_en#level-3-section1
Peterson AM, Le C, Dautrich T (2021) Measuring the change in health-related quality of life in patients using marijuana for pain relief. Med Cannabis Cannabinoids 4:114–120. https://doi.org/10.1159/000517857
doi: 10.1159/000517857
pubmed: 35224431
pmcid: 8832252
Bedford E (2020) • Marijuana user status and consumption by gender Canada 2019 | Statista. In: Statista, Canada. https://www.statista.com/statistics/587715/marijuana-consumption-canada-by-gender/ . Accessed 6 Jun 2022
Cooper ZD, Craft RM (2017) Sex-dependent effects of cannabis and cannabinoids: a translational perspective. Neuropsychopharmacology 43:34–51. https://doi.org/10.1038/npp.2017.140
doi: 10.1038/npp.2017.140
pubmed: 28811670
pmcid: 5719093
Vickery AW, Roth S, Ernenwein T et al (2022) A large Australian longitudinal cohort registry demonstrates sustained safety and efficacy of oral medicinal cannabis for at least two years. PLoS One. https://doi.org/10.1371/JOURNAL.PONE.0272241
doi: 10.1371/JOURNAL.PONE.0272241
pubmed: 36399463
pmcid: 9674134
Treves N, Mor N, Allegaert K et al (2021) Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis. Sci Rep. https://doi.org/10.1038/S41598-021-02770-6
doi: 10.1038/S41598-021-02770-6
pubmed: 34873203
pmcid: 8648720
Hines LA, Freeman TP, Gage SH et al (2020) Association of high-potency cannabis use with mental health and substance use in adolescence. JAMA Psychiat 77:1044–1051. https://doi.org/10.1001/JAMAPSYCHIATRY.2020.1035
doi: 10.1001/JAMAPSYCHIATRY.2020.1035
Solmi M, Radua J, Olivola M et al (2021) (2021) Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies. Mol Psychiatry 17:1–15. https://doi.org/10.1038/s41380-021-01161-7
doi: 10.1038/s41380-021-01161-7
Berrendero F, Romero J, García-Gil L et al (1998) Changes in cannabinoid receptor binding and mRNA levels in several brain regions of aged rats. Biochim Biophys Acta 1407:205–214. https://doi.org/10.1016/S0925-4439(98)00042-8
doi: 10.1016/S0925-4439(98)00042-8
pubmed: 9748581
Wang L, Liu J, Harvey-White J et al (2003) Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci U S A 100:1393. https://doi.org/10.1073/PNAS.0336351100
doi: 10.1073/PNAS.0336351100
pubmed: 12538878
pmcid: 298783
Le K (2019) A brief background on cannabis: from plant to medical indications. J AOAC Int 102:412–420. https://doi.org/10.5740/JAOACINT.18-0208
doi: 10.5740/JAOACINT.18-0208
Fernández-Bargiela N, Rotea-Salvo S, Margusino-Framiñán L et al (2022) Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study. Eur J Hosp Pharm 29:207–211. https://doi.org/10.1136/EJHPHARM-2020-002374
doi: 10.1136/EJHPHARM-2020-002374
pubmed: 33051194